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Introduction: Transcranial direct current stimulation (tDCS) is a potentially novel
strategy for cognitive enhancement in patients with mild or major neurocognitive
disorders. This study aims to assess the safety and efficacy of tDCS during cognitive
training on cognitive functioning in patients with mild or major neurocognitive disorders.
Methods: This study was primarily a single arm for safety, secondary a two-arm,
parallel, randomized, and sham-controlled trial for potential efficacy. Patients with mild or
major neurocognitive disorders were recruited. The participants and raters were blinded
to the group assignment. The participants in the active arm received tDCS (anodal;
F3, cathodal, Fp2, 2A, 20 min) twice daily for five consecutive days, whereas those
in the sham arm received the same amount of sham-tDCS. Calculation and reading
tasks were conducted in both arms as a form of cognitive intervention for 20 min
during tDCS. The primary outcome was the attrition rate during the trial in the active
arm, which is expected to be less than 10%. The secondary outcomes were the
between-group differences of adjusted means for several cognitive scales from baseline
to post-intervention and follow-up.
Results: Twenty patients [nine women (45%)], with a mean (standard deviation) age
of 76.1 years participated; nine patients (45%) with minor neurocognitive disorders
and 11 (55%) with major neurocognitive disorders were randomized, and 19 of them
completed the trial. The attrition rate in the active arm was 0%, with no serious adverse
events. Further, in the Intention-to-Treat analysis, patients in the active arm showed no
statistically significant improvement compared with those who received the sham in the
mean change scores of the mini-mental state examination [0.41; 95% CI (−1.85; 2.67) at
day five, 1.08; 95% CI (−1.31; 3.46) at follow-up] and Alzheimer’s disease assessment
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scale – cognition subscale [1.61; 95% CI (−4.2; 0.98) at day 5, 0.36; 95%CI (−3.19;
2.47) at follow-up].
Conclusion: These findings suggest that tDCS is safe and tolerable but causes no
statistically significant cognitive effects in patients with mild or major neurocognitive
disorders. Additional large-scale, well-designed clinical trials are warranted to evaluate
the cognitive effects of tDCS as an augmentation to cognitive training.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03050385.
Keywords: transcranial direct current stimulation, cognitive training, neurocognitive disorder, dementia, mild
cognitive impairment
INTRODUCTION
Dementia is a disorder characterized by cognitive decline
that interferes in patients’ daily living and social functioning.
Alzheimer’s disease (AD), is the most common cause of
developing dementia, and its progression is usually insidious and
slow. Often, a prodromal and transitional state exists, without
loss of independence, called mild cognitive impairment (MCI)
(Petersen et al., 1999; Gauthier et al., 2006). The progression of
dementia not only causes functional impairment in patients, it
also degrades the caregiver’s quality of life or social functioning
due to caregivers’ burden (Gill et al., 2017). Currently approved
pharmacotherapies, cholinesterase inhibitors, and memantine are
not disease-modifying and cannot revert the course of the disease,
although they show a slight improvement in cognitive scales
(Birks, 2006). Therefore, increasing focus has been placed on
delaying deterioration or conversion from MCI to AD and other
forms of dementia.
Recent studies have gradually revealed a few potentially
modifiable factors, such as physical inactivity, social isolation,
and depression (Gill et al., 2017). Further, a few cognitive
interventional studies have also been conducted. Cognitive
training generally includes guided practice on a set of
standardized tasks designed to reflect specific cognitive domains.
A recent meta-analysis indicated that the overall effect of
cognitive training on cognition in MCI was moderate (Hedges’
g = 0.35) and that in dementia was small (g = 0.26) (Hill
et al., 2017). However, many of these trials assessed short-
term cognitive outcomes. Moreover, based on the results
from randomized trials that lasted for at least 6 months,
cognitive training in patients with MCI suggested no effects
on performance, with low strength, and insufficient evidence
(Butler et al., 2018). Therefore, further strategies are awaited to
combat cognitive decline in such patients. Transcranial direct
current stimulation (tDCS) is a non-invasive neuromodulation
technique, which involves passing a direct electrical current
through the cerebral cortex, usually via two electrodes placed
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer dementia
assessment scale – cognitive subscale; CDR-J, clinical dementia rating-Japanese
version; CI, confidential interval; DLPFC, dorsolateral prefrontal cortex; FAB,
frontal assessment battery; LBD, lewy body disease; LTP, long-term potentiation;
MCI, mild cognitive impairment; MMRM, mixed-effect model repeated
measurement; MMSE, mini-mental state examination; SD, standard deviation;
tDCS, transcranial direct current stimulation.
on the scalp. One electrode serves as an anode and the other
functions as the cathode. The tDCS device generates and delivers
a small electric current (usually 1 to 2 mA) to different areas of
the brain (Yokoi et al., 2018). The basic mechanism of tDCS is
that the anodal tDCS increases neuronal excitability by causing
a depolarization of the resting potential, while the cathodal
tDCS hyperpolarizes the resting potential, thereby suppressing
neuronal excitability (Philip et al., 2017). The change in neuronal
excitability may lead to alteration in brain functioning in the
vicinity of the stimulated area (Meinzer et al., 2015). Further,
the alteration in brain functioning may also be explained
by the hypothesis that prolonged membrane polarization by
tDCS changes neuroplasticity through N-Methyl-D-aspartic acid
(NMDA) receptors, thereby leading to long-lasting aftereffects of
tDCS (Nitsche et al., 2003).
A recent meta-analysis of randomized controlled trials
indicated that tDCS may be effective on cognition in healthy
participants (Dedoncker et al., 2016); however, a meta-analysis of
randomized controlled trials on the effect of tDCS on cognition
in patients with dementia and MCI shows that tDCS is not
always effective overall (Inagawa et al., 2018). The discord among
the findings of these studies may be due to differences in the
electrode montage, stimulation parameters, and timing of tDCS
in the training tasks (Liu et al., 2017). Further, according to our
systematic review and meta-analysis (Inagawa et al., 2018), only
one study among the 11 previous studies on the effects of tDCS
on cognition in dementia and MCI described a plan to provide
sample size calculation. In addition, although we had planned to
estimate sample size from previous studies, no study assessed the
effect of tDCS combined with cognitive rehabilitation in patients
with MCI at July 2016, when we started this study. Therefore,
it was impossible to calculate sample size from the results of
previous studies. It is important to provide a priori sample size
calculation in order to gain sufficient statistical power to detect a
difference in clinical trials. However, many previous studies did
not provide sample size calculations and, thus, the results from
these studies may be false-negatives, when the results are actually
positive. Further, according to our meta-analytic review (Inagawa
et al., 2018), the quality of study designs in these previous studies
seems to be poor. In fact, many of them did not clearly state
allocation concealment, blinding of personnel, or any method
of handling missing data. These problems may overestimate the
effects of tDCS, although tDCS is actually not effective.
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Further, previous studies on tDCS revealed the beneficial
cognitive/anti-depressant effects of anodal tDCS in AD patients
undergoing simultaneous cognitive training (Hsu et al., 2015), in
depressive patients taking antidepressants (Brunoni et al., 2013),
and in MCI patients receiving physical therapy (Manenti et al.,
2016). Further, a randomized trial demonstrated that active tDCS,
but not sham, over DLPFC combined with a working memory
task showed greater improvement in healthy participants in
terms of the performance of an attention and working memory
test 1 month after the final treatment, compared with tDCS
alone (Martin et al., 2013). These studies indicate the possibility
of augmentation strategies of tDCS simultaneously with the
conduct of cognitive training for improving cognition in patients
with dementia and MCI.
The objectives of the proposed study are to assess the
safety and feasibility of tDCS during cognitive rehabilitation,
as well as to estimate potential efficacy applicable for further
confirmatory studies in patients with neurocognitive disorders.
Because combining tDCS with cognitive training may enhance
the benefits of tDCS, we hypothesize that tDCS will improve,
particularly when administered during cognitive tasks in patients
with these disorders.
MATERIALS AND METHODS
Trial Design
This exploratory study was a single-arm study in terms of
safety, while this was a two-arm, parallel, randomized, sham-
controlled trial for the assessment of potential efficacy, and
feasibility among 20 participants with a diagnosis of major
neurocognitive disorder or mild neurocognitive disorder based
on the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) (American Psychiatric Association, 2013). This study
is reported in accordance with the CONSORT (Consolidated
Standards of Reporting Trials) 2010 statement of information to
include when reporting a randomized trial, which was developed
to provide guidance in the form of a checklist of recommended
items to help improve the quality of a study design (Moher et al.,
2010; Supplementary Table S1).
Participants were supposed to be randomly assigned in
the ratio of 1:1 to one of two groups – an active group
or a sham group – using the order of entry into the study
and a computer-generated randomization list obtained using
a computer-generated randomization method, MUJINWARI
(IRUKA System Cooperation, Tokyo, Japan). This was done
to ensure a balanced allocation of the following factors across
groups: age range (55–60 years, 61–70 years, 71–80 years,
or 81–90 years), sex (male or female), and diagnosis (major
neurocognitive disorder or mild neurocognitive disorder).
This randomization method includes stratification for all of
those factors. The allocation sequence was concealed until
they completed the follow-up evaluations. tDCS device was
always kept at the back of participants’ visibility during
its administration so that participants did not recognize
allocation concealment. tDCS administrators only obtained
access to a computer-generated randomization list, and tDCS
administrators kept the allocation secret so that outcome raters
did not recognize allocation concealment. Both the participants
and raters were blinded to the group allocation; however, the
investigators and those administering the tDCS were not blinded
to the group allocation. In order to assess the quality of the
blinding, after completing the study on day 5, the participants
were asked to guess whether they were allocated to the active
or sham group of the study. Further, we evaluated demographic
and clinical characteristics, and used these data to provide
descriptive characteristics of the population, and to analyze
whether these characteristics could predict the outcomes. This
study was registered on ClinicalTrials.gov (NCT03050385).
Participants
Both inpatients and outpatients were recruited by referrals from
psychiatrists in a single academic hospital: National Center
of Neurology and Psychiatry in Tokyo, Japan; both male and
female patients were selected. The principal investigators or
sub investigators assigned participants to interventions. The
following were the key inclusion criteria: (a) subjects aged
between 55 and 90 years and diagnosed with either major
neurocognitive disorder or mild neurocognitive disorder, as
defined in DSM-5; (b) subjects taking a stable dose of anti-
dementia medications, such as cholinesterase inhibitors or
memantine, for at least 2 weeks preceding enrollment; and
(c) subjects who are able to walk independently, with or
without an aiding device. The following were the key exclusion
criteria: (a) subjects with severe psychotic symptoms requiring
antipsychotic treatment, (b) subjects estimated to be in need
of hospitalization within 6 weeks because of severe depression
and/or suicidal ideation, (c) subjects who have a clinical
contraindication to electroconvulsive therapy or tDCS, (d)
subjects with an MMSE score less than 18 or a clinical dementia
rating-Japanese version (CDR-J) global score of more than two,
(e) subjects who were unable to attend more than 2 days of the
trial, and (f) subjects for whom MMSE subscales of either “write a
sentence” or “copy a figure” was zero. The patients were carefully
assessed by a specialized psychiatrist before the trial. Because
of the safety of tDCS to date (Bikson et al., 2016), no specific
exclusion criteria were applied. Patients who were receiving anti-
dementia medications were not excluded, but they were required
to be receiving stable doses of these medications for at least
2 weeks prior to the first day of the administration of stimulation.
Intervention
Transcranial direct current stimulation was performed using a
specially developed battery-driven constant 1 × 1 low-intensity
tDCS (Model 1300A; Soterix Medical Inc., New York, NY,
United States) that delivers direct current through two saline-
soaked surface sponge electrodes (35 cm2) with a maximum
output of 2 mA. This device also has a switch off allocation. If
the administrator turned the switch on, the sham stimulation
was delivered; if the administrator turned the switch off, active
stimulation was delivered. During the stimulation, the device
was placed behind the participants, and their allocation was kept
secret so that they would not know which group they were
randomized to. The anode electrode was placed over the left
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dorsolateral prefrontal cortex (DLPFC) (F3) and the cathode
was placed over the contralateral supraorbital ridge (Fp2), using
the 10/20 electrode placement system in both active and sham
arms. This method of DLPFC placement has been established by
neuro-navigation techniques, as this method is relatively accurate
for localization (Herwig et al., 2003). The DLPFC was selected
because a previous study on healthy participants indicated that
tDCS over DLPFC had beneficial effects on working memory
(Martin et al., 2013). The cathode electrode was placed over
the contralateral supraorbital area, which was similar to recent
tDCS studies on cognitive functioning in patients with MCI
(Manenti et al., 2016), Alzheimer’s dementia (Khedr et al.,
2014), and schizophrenia (Narita et al., 2017). It must be noted
that for aging populations, stimulation with 2 mA has been
shown to be safe. Actually, no severe adverse events due to
tDCS with 2 mA have been reported (Bikson et al., 2016). The
participants in the active arm received active tDCS at a constant
current with an intensity of 2 mA for 20 min per session,
with two sessions per day for 5 consecutive days. Those in the
sham arm received the same treatment as those in the active
arm, but the overall active stimulation period was only 60 s,
including the 30 s for both the fade-in and fade-out periods.
For the other periods, the stimulator remained active but did
not generate current for 20 min in each session. Therefore,
those in the sham arm usually experienced an initial itching
sensation but received no current for the remainder of the
session. All the participants received both tDCS (either active
or sham) and cognitive training task for 20 min per session.
On each day, the second active or sham tDCS session was
conducted at least 20 min after the end of the first tDCS session
in order to take into consideration the aftereffects of tDCS. In
other words, the interval between the first and second tDCS
session was 20 min.
These tasks comprised an initial 10 min calculation task,
followed by a 10 min language task in Japanese. During the
calculation task, participants solved basic arithmetic questions –
such as single-digit addition, subtraction, and multiplication –
as quickly and accurately as possible. During the language
tasks, which included the Kanji writing task and the Kanji
connecting task, participants answered questions related to
Japanese Kanji letters. All the questions were printed on A4 sheets
(210 mm × 297 mm). In the Kanji writing task, each participant
was asked to interpret the meaning of hiragana characters and
to write letters in Kanji. The participants performed a Kanji
connecting task on a 10 × 10 grid, which contained a Kanji
letter in each grid. In a separate table, there was a list of 20
different Kanji letters. In this task, the participants began from
the first Kanji letter in the upper-left corner of the 10 × 10 grid
(Figure 1a). Next, the participants were instructed to look at the
Kanji letters on the right and toward the bottom of the first Kanji
letter (Figure 1b) and match it with a Kanji letter included in the
list of 20 different Kanji letters in the table (Figure 1c). When
one of them would match, they connected this Kanji letter to the
first Kanji by drawing a line from one to another (Figure 1d). In
the next step, the new Kanji letter would take the place of the first
Kanji letter (Figure 1e). The participants were asked to repeat this
process for all the Kanji letters until they reached the Kanji letter
in the bottom-right corner of the grid (Figure 1f).
The difficulty and complexity of the cognitive tasks were the
same across sessions, but the content was different. We did
not calculate the scores that could be obtained from the tasks.
A previous randomized controlled trial indicated that similar
FIGURE 1 | Kanji connection task. (a) The participants began from the first Kanji letter in the upper-left corner of the 10 × 10 grid. (b) The participants were
instructed to look at the Kanji letters on the right and toward the bottom of the first Kanji letter. (c) The participants were instructed to match it with a Kanji letter
included in the list of 20 different Kanji letters in the table. (d) When one of them would match, they connected this Kanji letter to the first Kanji by drawing a line from
one to another. (e) The new Kanji letter would take the place of the first Kanji letter. (f) The participants were asked to repeat this process for all the Kanji letters until
they reached the Kanji letter in the bottom-right corner of the grid.
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working memory tasks (reading and simple arithmetic problems)
as the one in our pilot study improve executive functions, verbal
episodic memory, focus attention, and processing speed in elderly
patients who are healthy (Nouchi et al., 2016). The rationale for
using these working memory tasks is that the training activates
the bilateral prefrontal cortex (Arsalidou and Taylor, 2011). We
also chose this task because the task was familiar to Japanese
elderly population and feasible to be conducted among patients
with dementia (Kawashima et al., 2005). We were interested
in investigating the effects of tDCS on global cognition when
combined with the cognitive training task commonly used for the
elderly population in Japan, in order to ensure whether clinically
meaningful effects can be obtained by adding multisession
tDCS to cognitive training using common cognitive measures of
MMSE and ADAS-Cog.
Outcomes
As this was the first phase of an exploratory feasibility trial,
a sample size of 20 individuals, including sham, was adapted. In
the intervention group, the primary outcome was the attrition
rate during the trial, which is expected to be less than 10%. We
selected the attrition rate as the primary outcome because it
was important to first assess the safety and feasibility of tDCS
in Japanese patients with neurocognitive disorders due to the
fact that, to the best of our knowledge, no previous studies
were found in such patients receiving tDCS while simultaneously
being engaged in cognitive rehabilitation in Japan on July, 2016
when we started this study. The secondary outcomes were
between-group differences in mean ADAS-Cog, MMSE, frontal
assessment battery (FAB), and CDR-J scores from the baseline.
We selected ADAS-Cog (whose score ranged from 0 to 70) and
MMSE (whose score ranged from 0 to 30) for the assessment
of global cognition, FAB (whose score ranged from 0 to 18) for
the evaluation of frontal lobe functions, and CDR (whose score
ranged from 0 to 3) for the estimation of the severity of dementia.
All the above-mentioned outcome measures were scored by a
psychologist after a clinical interview, who was blinded to group
allocation. The outcome measures were assessed at the baseline,
at the end of the final stimulation, and 2 weeks after the final
stimulation (Supplementary Table S2).
Data Collection Methods and Data
Monitoring
The assessments were conducted at the baseline, immediately
after the intervention, and 2 weeks after the end of the
intervention (Supplementary Table S2). Baseline and follow-
up evaluations were conducted by experienced psychologists,
who were blinded to the group assignments. The outcome data
was sent to an independent data monitor, and neither the
investigators nor the raters handled any data directly throughout
the study. The data were initially recorded on paper files, with
each participant assigned to a code number. These files were
stored in a locked security box. Upon completion of the follow-up
data collection, the data was sent to an independent data tester for
cleaning up. The data monitor center also oversaw and reviewed
the progress of the trial. If a participant decided to withdraw
their consent, we allowed that participant to stop at any time. We
also ceased the intervention if we observed any severe adverse
events like burning. In this pilot study, the Efficacy and Safety
Assessment Committee, which comprised members that were
independent of the research, in the National Center of Neurology
and Psychiatry checked and assessed whether or not this clinical
trial was conducted safely and appropriately. The committee
was called upon to decide whether it is possible to continue
the trial or whether the research protocol must be revised in
cases of either severe adverse events or protocol violations.
The committee also performed this procedure by checking the
documents of this trial in the intermediate period when five
participants completed or discontinued their participation in this
trial. The safety questionnaire on adverse events was established
at the time according to the guidelines published in a recent
consensus paper (Brunoni et al., 2011).
Statistical Analysis
We conducted an intention-to-treat analysis for patients who
were randomized to either the active or sham arms; in addition,
we summarized demographic data for all patients. Further, we
calculated the point estimate of tDCS-related dropout proportion
in the intervention group, where we checked whether the
estimate was less than 10%. The exact confidential intervals
(CIs) of this binomial proportion (Clopper and Pearson, 1934)
were assessed. In order to evaluate the mean treatment effect,
we conducted mixed models for repeated measures (MMRM)
analysis to detect changes from baseline in ADAS-Cog, MMSE,
FAB, and CDR-J at day 5 and follow-up. The MMRM analysis
models included the covariates of age (55–60 years, 61–70 years,
71–80 years, or 81–90 years), sex (male or female), and disease
(dementia or MCI), which were the stratification factors of
dynamic allocation. This MMRM analysis models had treatment
groups, time, group-by-time interaction, age, sex, diagnosis, and
baseline as a fixed effect and unstructured covariance structure.
Fisher’s exact test was used to assess the integrity of blinding. We
used STATA 14 (StataCorp LP, College Station, TX, United States)
and SAS version 9.4 to conduct the statistical analysis.
RESULTS
Participants
Of the 21 participants who agreed to provide written consent,
20 were randomized to either the active or sham arms. Seven
patients (five patients had AD, one had lewy body disease
(LBD), and the other had the other type of etiology) were
allocated to the active arm, while 13 patients (11 patients
had AD, one had LBD, and the others had unspecified types
of neurocognitive disorders) were allocated to the sham arm.
Further, 19 participants (seven in the active arm and 12 in the
sham arm) received all 10 tDCS sessions and completed the
final assessment. All patients in tDCS group were outpatients.
Two participants withdrew from the study: one withdrew during
the intervention phase, and one before randomization. Figure 2
depicts a flow chart on participants’ selection, and Table 1
presents baseline characteristics. Recruitment and follow-up were
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FIGURE 2 | Flow chart of participant selection.
conducted from July 2016 until July 2017 because more than
20 participants finished follow-up examinations. 20 participants
were included for statistical analysis.
Primary Outcome
The primary outcome was an attrition rate in the intervention
group. The attrition rate in the group was 0%, with no
TABLE 1 | Demographics and clinical characteristics (n = 20).
Active group Sham group
Mean ± SD or n (%)
7 (100%) 13 (100%)
Age (year) 76.6 ± 5.7 76.2 ± 7.7
Female 4 (57.1%) 6 (46.2%)
Major neurocognitive disorder 3 (42.9%) 7 (53.8%)
Right-handed 7 (100%) 13 (100%)
Duration since diagnosis (year) 0.9 ± 1.2 1.2 ± 1.5
Family history
Dementia 3 (42.9%) 3 (23.1%)
Mental disorder 0 (0%) 0 (0%)
Neurological disorder 1 (14.3%) 1 (7.7%)
Medication over the past 6 months
Antidepressant, antipsychotics 1 (16.7%) 3 (23.1%)
Benzodiazepine 3 (42.9%) 4 (30.8%)
Cholinesterase inhibitors 4 (57.1%) 10 (76.9%)
Past history
Substance abuse disorder 1 (14.3%) 0 (0%)
Schizophrenia 0 (0%) 0 (0%)
Mood disorder 0 (0%) 0 (0%)
Neurologic disorder 0 (0%) 2 (15.4%)
Head trauma 1 (14.3%) 2 (15.4%)
Visits to day care center for seniors 1.3 ± 2.6 0 ± 0
SD, standard deviation.
requirements of hospitalization, trial discontinuation, or any
specific treatment in the active arm. The CIs of this proportion
were from 0.0 to 41.0%.
Secondary Outcomes
MMSE
The differences in adjusted means between groups for MMSE
scores were 0.41 [95% CI: −1.85 to 2.67] (p = 0.705) at day
five, and 1.08 [95% CI: −1.31 to 3.46] (p = 0.352) at follow-
up, respectively (Table 2). There was no statistical significance
in the between-group difference between the active and sham
groups. Supplementary Table S3 presents the change scores
in adjusted mean difference from the baseline in each group.
Figure 3 illustrates the mean values and standard deviations
(SDs) at each point.
TABLE 2 | The differences in adjusted means between groups for each cognitive
scale in the MMRM analysis.
Active tDCS vs. Sham
Clinical Post-treatment Two-weeks follow
studies from baseline up from baseline
95% 95%
Difference CI p Difference CI p
MMSE 0.41 −1.85 2.67 0.705 1.08 1.31 3.46 0.352
ADAS-Cog −1.61 −3.19 2.47 0.205 −0.36 −3.19 2.47 0.791
FAB −2.27 −6.17 1.63 0.233 −3.01 −6.46 0.45 0.083
CDR 0.06 −0.09 0.22 0.404
MMRM, mixed-effect model repeated measurement; tDCS, transcranial direct
current stimulation; 95% Cl, 95% confidential intervals; MMSE, mini-mental
state examination; ADAS-Cog, Alzheimer dementia assessment scale – cognitive
subscale; FAB, frontal assessment battery; CDR-J, clinical dementia rating-
Japanese version.
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FIGURE 3 | The change scores in adjusted mean difference from baseline on ADAS-Cog and MMSE. In order to understand the mean change from baseline in each
group easily, baseline scores in each group were shown as zero in this graph.
ADAS-Cog
The differences in adjusted means between groups for ADAS-Cog
scores were 1.61 [95% CI:−4.2 to 0.98] (p = 0.205) at day five and
0.36 [95% CI: −3.19 to 2.47] (p = 0.791) at follow-up (Figure 3).
There was no statistically significant difference between the active
and sham arms. Supplementary Table S3 presents the change
scores in the adjusted mean difference from baseline in each
group. Figure 3 illustrates the mean values and SDs at each point.
FAB
The differences in adjusted means between groups for FAB scores
were −2.27 [95% CI: −6.17 to 1.63] (p = 0.233) at day five and
−3.01 [95% CI: −6.46 to 0.45] (p = 0.083) at follow-up. FAB
showed a dip in the active arm at both day five and follow-up,
but no statistically significant differences were found between the
groups. Supplementary Table S3 presents the change scores in
the adjusted mean difference from baseline in each group.
CDR
The differences in adjusted means between groups for CDR
scores were 0.06 [95% CI: −0.09 to 0.22] (p = 0.404) at follow-
up. Supplementary Table S3 presents the change scores in the
adjusted mean difference from baseline in each group.
Adverse Events
We found neither severe adverse events nor the need for
medications caused by adverse events in each group. Table 3
presents adverse events related to tDCS.
Integrity of Blinding
In the sham and active groups, seven of 12 participants (58.3%)
and three of seven participants (42.9%), respectively, correctly
identified the allocation group (p = 1.000, as assessed by Fisher’s
exact test). Thus, participants were unable to guess their actual
group beyond that by chance.
DISCUSSION
Using data from a small sized sample, no cognitive effects of
tDCS were detected in this pilot study; however, this is certainly
not definitive because of the insufficient sample size used in this
study. Further studies using a larger sample size are warranted
in order to arrive at a clear conclusion regarding whether or
not tDCS is effective for improving cognition in patients with
mild or major neurocognitive disorders and also to evaluate the
generalizability of this pilot study. Moreover, we did not adjust
for multiplicity because the primary objective of this study was
to assess the safety and feasibility of tDCS in Japanese elderly
patients with neurocognitive disorders, and the secondary aim
was to exploratorily estimate potential efficacy applicable for
further proof-of-concept studies to demonstrate the effects of
tDCS on cognition in patients with neurocognitive disorders.
Apart from that, the augmentation strategy in this pilot study
should have been more sophisticated. Although proof of concept
has been indicated, whereby anodal stimulation over DLPFC
during a working memory task led to enhanced performance the
TABLE 3 | Adverse effects related to tDCS reported by patients in each group.
tDCS Sham p
Headache (n, %) 1 (14.3%) 5 (38.5%) 0.354
Neck pain (n, %) 0 (0%) 2 (15.4%) 0.521
Scalp pain (n, %) 0 (0%) 4 (30.8%) 0.249
Tingling (n, %) 3 (42.9%) 9 (69.2%) 0.428
Itching (n, %) 1 (14.3%) 3 (30.8%) 1.000
Burning sensation (n, %) 2 (28.6%) 4 (30.8%) 1.000
Skin redness (n, %) 2 (28.6%) 2 (15.4%) 0.587
Sleepiness (n, %) 1 (14.3%) 2 (15.4%) 1.000
Trouble concentrating (n, %) 1 (14.3%) 1 (7.7%) 1.000
Acute mood change (n, %) 0 (0%) 1 (7.7%) 1.000
Others (n, %) 0 (0%) 0 (0%) 1.000
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next day (Martin et al., 2013), the cognitive training task used
in this pilot study is not exactly the same as that employed in
previous studies. Moreover, the Kanji connection task is short
and tough as compared with that in previous studies. A previous
study indicates that those trainees who put more effort into
training were more anxious or depressed, and showed lesser
improvement in cognition (McAvinue et al., 2013). Therefore, it
may be necessary not only to modify the tDCS protocol but also
to optimize the cognitive task in future trials.
Further, the target population may not have been optimal.
A previous randomized controlled trial indicates that tDCS is not
effective on global cognition assessed by ADAS-Cog in patients
with moderate and severe dementia with apathy. The authors
discuss that in order to gain cognitive benefits of anodal repetitive
tDCS, it is necessary to have at least some remaining neuronal
function to promote plasticity, which may not be possible in
aged patients with AD. In this study, the target population may
have been patients in an early stage of the disease, like MCI.
Moreover, the difference between mild neurocognitive disorders
and major neurocognitive disorders is the interference with
independence in daily activities. Then, cognitive deficits in mild
neurocognitive disorders may be stable or even reversible, but
those in major neurocognitive disorders may be continuous or
even progressive. These differences between the mild and major
disorders especially for the potential difference in the course of
cognitive change may have confounded the results presenting the
after-treatment cognitive changes from baseline although we did
include the variable as a covariate in the analysis. A preliminary
randomized sham-controlled trial indicated that comparisons
of anodal tDCS for the DLFPC group (2 mA, 25 min daily
for 10 days) vs. the sham group revealed significant interaction
between time and treatment for MMSE scores post-stimulation,
1 month later, and 2 months later in 22 patients (11 in each group)
with mild-to-moderate Alzheimer’s dementia (p = 0.04) (Khedr
et al., 2014). Another preliminary randomized sham-controlled
trial indicated that anodal tDCS over the DLPFC group (2 mA,
25 min daily for 10 days) vs. the sham group showed a significant
interaction between time and treatment (p = 0.0041) on the
Parkinson’s disease cognitive rating scale at the post-stimulation
point and 3-month follow-up period in 20 patients (10 in each
group) with MCI in Parkinson’s disease (Manenti et al., 2016). On
the other hand, no significant effect of anodal tDCS over DLPFC
was found on the Apathy scale (p = 0.55 for repeated measures)
or ADAS-Cog (p > 0.40) in 40 patients (20 in each group) with
moderate-to-severe AD compared to the sham group (Suemoto
et al., 2014). Moreover, tDCS may not be effective in global
cognition in these patients. Although a few studies show potential
cognitive benefits, a functional trade-off has been suggested in
which improvement in a single cognitive domain comes at the
cost of decline in another one (Philip et al., 2017). In addition,
the effect of tDCS appears to be site-specific; thus, the effect of
tDCS in itself may not sufficiently transfer to other brain regions
to improve global cognition (Kim et al., 2014).
In order to determine whether or not the effect of tDCS on
cognition in neurocognitive disorders is clinically meaningful,
one of the possible options is to compare the effect of tDCS with
that of the first-line standard treatment. Although Cholinesterase
inhibitors (ChE-Is) have never been approved for standard
treatment in patients with MCI in Japan, they are considered
to be the first-line pharmacological agent for mild to moderate
AD. ChE-Is work by inhibiting the breakdown of acetylcholine,
an important neurotransmitter related to memory, by blocking
the enzyme acetylcholinesterase. The between-group difference
in mean changes of MMSE was 1.37, according to a systematic
review and meta-analysis of unconfounded, double-blinded,
randomized, placebo-controlled trials designed to evaluate the
efficacy of patients with dementia due to AD, in which treatment
with a ChE-I was administered for approximately 6 months
(Birks, 2006). If the effect size obtained from the ongoing
phase-II randomized trial is similar to that in our pilot study,
which was 1.08 at follow-up, tDCS could be a potential tool
for alleviating cognitive deficits in those patients. Further, the
differences in adjusted means between groups for ADAS-Cog
scores at day five was −1.61 (p = 0.205) (Figure 3). Further trials
are warranted to evaluate whether these cognitive benefits can be
generalized to the larger population in MCI and mild dementia
in this tDCS protocol.
The strength of this study is that it has a relatively low
bias risk as compared with previous studies. Although tDCS
administrators were not blinded, both participants and raters
were blinded. A random sequence was generated through
computers, and allocation was concealed until the disclosure of
the data; blinding was well integrated. Further, all pre-specified
outcomes were shown after registration on ClinicalTrials.gov.
The dropout rates were low in both groups: 0% in the active group
and 7.69% in the sham group. These indicate the quality of this
study. Another strength of our study is the novelty that, to the
best of our knowledge, this is the first study to assess optimized
tDCS protocol combined with cognitive training in patients with
both MCI and mild dementia. Further, our pilot study indicated
that tDCS combined with cognitive training was safe and feasible.
In addition, we selected ADAS-Cog and MMSE because these
scales are the screening tools that are most commonly used to
measure cognitive deficits in clinical settings.
This study has a few additional limitations. First, the follow-
up period is too short to evaluate changes in disease progression
and to test whether additional interventions are needed over
time. Second, cognitive training tasks used in this pilot study
are not entirely the same as those used in previous studies,
which indicates that calculation tasks and reading tasks improve
executive functions, verbal episodic memory, focus attention,
and processing. Third, our cognitive training protocol is short
and tough compared to that of previous studies. This may have
caused psychological stress among participants, which may have
decreased the effect of cognitive training (McAvinue et al., 2013).
Fourth, our pilot study only selected MMSE and ADAS-Cog total
scores for the assessment of global cognition and FAB for the
evaluation of frontal lobe cognitive function. In future studies,
a standard scale, like the repeatable battery for the assessment
of neuropsychological status (RBANS), is an appropriate choice
to comprehensively assess the global cognition and cognitive
domains separately and to gain statistical power enough to
assess the meaningful cognitive benefits in patients with early
stages of neurocognitive disorders. For example, RBANS may
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be well suited because it is a brief and comprehensive battery
consisting of the following indices: memory, attention, language,
visuospatial/constructional, and total scores. This scale enables
raters to simultaneously assess global cognition and several
other domains of cognition, including memory, attention, and
language. Fifth, we selected MMRM analysis for multiple
outcome measures and several time points, so the results obtained
from those measures should be interpreted carefully. Future trials
with a proper sample size calculation for one primary outcome
may provide meaningful results. Sixth, a small sample size may
lead to lack of statistically significant power. It is important
to provide a priori sample size calculation in order to gain
sufficient statistical power to detect a difference in clinical trials.
However, we did not provide it because it was necessary to first
assess the safety and feasibility of tDCS in Japanese patients
with neurocognitive disorders, as, to the best of our knowledge,
this is the first pilot study of tDCS in such patients. Therefore,
the results obtained from this study may well lack statistical
power to detect a difference between the active and sham arms.
If the primary outcome of a future trial lies in the differences
of adjusted means between groups for ADAS-Cog scores at day
five, the minimal sample size with statistical power over 0.8 is
estimated to be 46 in each group; this is based on the assumption
that the between-group difference in ADAS-Cog scores is −1.61
and its SD is 2.70. Based on this sample size calculation, we
have initiated a phase-II randomized, sham-controlled trial of
tDCS on cognition in MCI and mild dementia. This trial has
been registered in the Japan Registry of Clinical Trials (protocol
number: jRCTs032180016). Seventh, the patients were supposed
to be randomized to the treatment groups with a 1:1 ratio but the
outcome of the allocation was 7:13. That was because too many
factors were included in the factors for minimization techniques
in spite that the sample size was small. Eighth, the results may
be interpreted carefully because we conducted statistical tests
for a variety of outcome groups without taking multiplicity into
consideration because this trial was an exploratory trial.
In conclusion, tDCS is safe and tolerable in the context of
cognitive rehabilitation. We found no statistically significant
cognitive effects of tDCS in patients with mild or major
neurocognitive disorders. Further trials with larger samples may
clarify the efficacy of tDCS on global cognition and several
cognitive domains in such patients.
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